Home

Clinical data presented at the 2019 European Cardio-Thoracic Surgery (EACTS) annual meeting (3-5 October, Lisbon, Portugal), from two prospective trials of the VEST external stent for vein grafts during coronary artery bypass surgery (CABG), showed low major adverse cardiac and cerebrovascular events (MACCE) rates up to three years, excellent patency rates and a significant reduction in the progression of vein graft disease.

David Taggart (John Radcliffe Hospital, Oxford, UK) presented the results of the VEST III trial at the late breaking clinical trials session. VEST III is a randomized controlled trial that enrolled 184 patients in 14 centres across Germany, Austria, Israel and the UK. At two years, the trial met its primary and secondary endpoints, showing superior perfect patency rates (Fitzgibbon I) of externally stented vein grafts compared to the control group (66.4% vs 53.6%, p value = 0.02) and a highly significant reduction of 25% (p value <0.001) in both intimal area and thickness assessed by intravascular ultrasound (IVUS).

“The results of the VEST III trial confirm our previous observations regarding the bio-mechanical effects of external stenting,” said Taggart. “This is another milestone in our ongoing efforts to improve coronary surgery and patients’ quality of life. As the principle investigator of the first-in-human VEST I trial in 2011, and someone who has closely followed the evolution of this technology in the last 10 years, it is very satisfying to see how the combined effort of surgeons, scientists and innovators has led to a technology with high clinical impact.”

Luca Weltert (European Hospital, Rome, Italy) presented interim results from a led all comers study that evaluated angiographic and clinical outcomes in 51 patients. The majority of patients underwent off pump CABG (77%) and all vein grafts were supported with the VEST external stent. CT angiography was performed at one year and patients were prospectively followed every six months for MACCE.

Although the average age of the study cohort was 73.5, with 32% of patients having had a prior primary coronary intervention (PCI), at average follow-up of 3 years, MACCE rates were 2% with only one patient requiring revascularisation to a de-novo coronary lesion. At one year, CT angiography demonstrated 100% patency of the VEST externally supported vein grafts.

“It is very encouraging to see that “real world” data supports the evidence from randomized trials,” said Prof. Luca Weltert. “Very often, we see big gaps between clinical results of randomized cohorts, which are highly selective in nature, and the results in our day to day practice. Our interim follow-up data shows that at 3 years, clinical and angiographic results are superior compared to those observed in published randomised trials.”

Source CardioVascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: VEST external stent demonstrates low event and disease rates in two prospective trials

Chia sẽ qua google bài: VEST external stent demonstrates low event and disease rates in two prospective trials

Chia sẽ qua twitter bài: VEST external stent demonstrates low event and disease rates in two prospective trials

Chia sẽ qua MySpace bài: VEST external stent demonstrates low event and disease rates in two prospective trials

Chia sẽ qua LinkedIn bài: VEST external stent demonstrates low event and disease rates in two prospective trials

Chia sẽ qua stumbleupon bài: VEST external stent demonstrates low event and disease rates in two prospective trials

Chia sẽ qua icio bài: VEST external stent demonstrates low event and disease rates in two prospective trials

Chia sẽ qua digg bài: VEST external stent demonstrates low event and disease rates in two prospective trials

Chia sẽ qua yahoo bài: VEST external stent demonstrates low event and disease rates in two prospective trials

Tin tức liên quan

Vesteck completes first-in-human use of several Suture-Tight devices

Age is just a number: Individual patient data meta-analysis probes safety of CEA in the elderly

Artificial intelligence can predict risk of complications after endovascular aneurysm repair

Bluegrass Vascular announces Journal of Vascular Surgery paper reporting use of Surfacer system

Vascular access creation: EndoAVF keeps future options open, but is not a replacement for surgical fistulas

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.